Sellas Life Sciences gains WT1 cancer vaccine rights from Memorial Sloan Kettering

5 September 2014

Swiss/Greek pharmaceutical and clinical research group Sellas Life Sciences Group has signed an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development, marketing, and commercialization of MSK's proprietary WT1 cancer vaccine.

"This collaboration underscores Sellas’ commitment to innovative therapies for major unmet medical needs and is of paramount importance and a significant milestone for us," said Angelos Stergiou, chairman and chief executive of the firm, adding:"We believe this will enable us to accelerate the development of the WT1 vaccine, and we would like to congratulate the Memorial Sloan Kettering research team for their superb work identifying very effective peptide sequences for this vaccine."

Initial focus will be leukemia, mesothelioma and myeloma

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK